Study summary

An antibody against antibody-making plasma cells raised platelets in 91% at the top dose

Mezagitamab phase 2 · 41 people, phase 2 · Published April 2026, New England Journal of Medicine

91%platelet response at 600 mg, vs 23% with placebo

What was tested

Mezagitamab, an anti-CD38 antibody injected weekly for 8 weeks that removes plasma cells making anti-platelet antibodies, against placebo, in chronic ITP.

What they found

What it means

Led to the phase 3 trial now under way.

N Engl J Med, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.